BioAtla, Inc.
NASDAQ:BCAB
2.09 (USD) • At close November 1, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | BioAtla, Inc. |
Symbool | BCAB |
Munteenheid | USD |
Prijs | 2.09 |
Beurswaarde | 101,021,613 |
Dividendpercentage | 0% |
52-weken bereik | 1.14 - 4.02 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Dr. Jay M. Short Ph.D. |
Website | https://www.bioatla.com |
An error occurred while fetching data.
Over BioAtla, Inc.
BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ovarian cancer. It
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)